Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of HL-300 ointment in adults with mild to moderate atopic dermatitis
CTR20261611Phase 2Active
- Sponsor
- Highlight Pharmaceutical
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HL-300 in atopic dermatitis (AD), sponsored by Highlight Pharmaceutical. Started May 2026; status: active.
02
Drugs
HL-300
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20261611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261611.